JP2011502513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502513A5 JP2011502513A5 JP2010533204A JP2010533204A JP2011502513A5 JP 2011502513 A5 JP2011502513 A5 JP 2011502513A5 JP 2010533204 A JP2010533204 A JP 2010533204A JP 2010533204 A JP2010533204 A JP 2010533204A JP 2011502513 A5 JP2011502513 A5 JP 2011502513A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- therapy
- genes
- cancer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 238000011122 anti-angiogenic therapy Methods 0.000 claims description 54
- 239000000523 sample Substances 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 35
- 238000011319 anticancer therapy Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 230000008901 benefit Effects 0.000 claims description 23
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 18
- 206010038389 Renal cancer Diseases 0.000 claims description 18
- 201000010982 kidney cancer Diseases 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000013074 reference sample Substances 0.000 claims description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000004043 responsiveness Effects 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 229940124650 anti-cancer therapies Drugs 0.000 claims description 3
- 238000011331 genomic analysis Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 230000008569 process Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002137 anti-vascular effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98688407P | 2007-11-09 | 2007-11-09 | |
| PCT/US2008/082456 WO2009061800A2 (en) | 2007-11-09 | 2008-11-05 | Methods and compositions for diagnostic use in cancer patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011502513A JP2011502513A (ja) | 2011-01-27 |
| JP2011502513A5 true JP2011502513A5 (enExample) | 2012-12-27 |
Family
ID=40342593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533204A Withdrawn JP2011502513A (ja) | 2007-11-09 | 2008-11-05 | 癌患者における診断用途のための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090123930A1 (enExample) |
| EP (1) | EP2222874A2 (enExample) |
| JP (1) | JP2011502513A (enExample) |
| KR (1) | KR20100095571A (enExample) |
| CN (1) | CN101910416A (enExample) |
| AU (1) | AU2008324782A1 (enExample) |
| BR (1) | BRPI0817158A2 (enExample) |
| CA (1) | CA2703258A1 (enExample) |
| IL (1) | IL205246A0 (enExample) |
| MX (1) | MX2010005057A (enExample) |
| RU (1) | RU2010123381A (enExample) |
| WO (1) | WO2009061800A2 (enExample) |
| ZA (1) | ZA201002808B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2766403A1 (en) * | 2009-07-13 | 2011-01-20 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| WO2011033006A1 (en) * | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
| JP2013538338A (ja) * | 2010-07-19 | 2013-10-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
| SG10201505593VA (en) * | 2010-07-19 | 2015-09-29 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| BR112013031019A2 (pt) * | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | teste diagnóstico molecular para câncer |
| EP2802346B1 (en) * | 2012-01-13 | 2018-09-12 | F.Hoffmann-La Roche Ag | Biological markers for identifying patients for treatment with vegf antagonists |
| KR20150024342A (ko) * | 2012-06-26 | 2015-03-06 | 에프. 호프만-라 로슈 아게 | 유방암을 치료하기 위한 베바시주맙 조합 요법에 대한 혈장 바이오마커 |
| US11091809B2 (en) | 2012-12-03 | 2021-08-17 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
| SG11201602019XA (en) * | 2013-09-17 | 2016-04-28 | Agency Science Tech & Res | Multigene assay for prognosis of renal cancer |
| GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| EP3230498B1 (en) * | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| KR101903522B1 (ko) * | 2015-11-25 | 2018-11-23 | 한국전자통신연구원 | 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치 |
| TW202528738A (zh) * | 2023-11-09 | 2025-07-16 | 昇捷生物科技股份有限公司 | 基於α-1抗胰蛋白酶生物標記物之癌症檢測方法及套組 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030027216A1 (en) * | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
| CA2604549A1 (en) * | 2005-04-13 | 2006-10-19 | Oncotest Gmbh | Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds |
| CA2648106A1 (en) * | 2006-03-31 | 2007-11-01 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
-
2008
- 2008-11-05 JP JP2010533204A patent/JP2011502513A/ja not_active Withdrawn
- 2008-11-05 BR BRPI0817158 patent/BRPI0817158A2/pt not_active IP Right Cessation
- 2008-11-05 MX MX2010005057A patent/MX2010005057A/es not_active Application Discontinuation
- 2008-11-05 WO PCT/US2008/082456 patent/WO2009061800A2/en not_active Ceased
- 2008-11-05 CN CN2008801243215A patent/CN101910416A/zh active Pending
- 2008-11-05 AU AU2008324782A patent/AU2008324782A1/en not_active Abandoned
- 2008-11-05 RU RU2010123381/15A patent/RU2010123381A/ru not_active Application Discontinuation
- 2008-11-05 CA CA2703258A patent/CA2703258A1/en not_active Abandoned
- 2008-11-05 US US12/265,143 patent/US20090123930A1/en not_active Abandoned
- 2008-11-05 EP EP08846956A patent/EP2222874A2/en not_active Withdrawn
- 2008-11-05 KR KR1020107012551A patent/KR20100095571A/ko not_active Withdrawn
-
2010
- 2010-04-21 ZA ZA2010/02808A patent/ZA201002808B/en unknown
- 2010-04-22 IL IL205246A patent/IL205246A0/en unknown
- 2010-11-19 US US12/950,824 patent/US20110151468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502513A5 (enExample) | ||
| Huang et al. | Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis | |
| Zhang et al. | Current opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy | |
| Wei et al. | Ten years of EWAS | |
| Zhu et al. | A long non-coding RNA signature to improve prognosis prediction of gastric cancer | |
| Beuselinck et al. | Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib | |
| Wan et al. | Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome | |
| Formica et al. | Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab | |
| de Haas et al. | Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy | |
| RU2010123381A (ru) | Способ и композиции для диагностического применения у раковых пациентов | |
| JP2007507222A5 (enExample) | ||
| JP2014520529A5 (enExample) | ||
| US20120015906A1 (en) | Uses of bortezomib in predicting survival in multiple myeloma patients | |
| JP2012532628A5 (enExample) | ||
| Voorwerk et al. | PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial | |
| Kiss et al. | MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX | |
| Yan et al. | Influence of component 5a receptor 1 (C5AR1)− 1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria | |
| JP2017525337A5 (enExample) | ||
| Kovacova et al. | MiR-376b-3p is associated with long-term response to sunitinib in metastatic renal cell carcinoma patients | |
| WO2010054379A3 (en) | Gene signature for predicting prognosis of patients with solid tumors | |
| Zou et al. | ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer | |
| Bristow | Pharmacogenetic targeting of drugs for heart failure | |
| Buchbinder et al. | Biomarkers in melanoma: Lessons from translational medicine | |
| Jeon et al. | Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans | |
| JP2019533987A5 (enExample) |